<DOC>
	<DOCNO>NCT00389792</DOCNO>
	<brief_summary>The purpose study determine safety efficacy investigational antiarrhythmic drug ( ATI-2042 ) treatment atrial fibrillation patient dual chamber pacemaker .</brief_summary>
	<brief_title>Efficacy Safety Study Antiarrhythmic Drug Treat Atrial Fibrillation Patients With Pacemakers</brief_title>
	<detailed_description>ATI-2042 develop alternative amiodarone , consider first-line therapy patient atrial fibrillation know serious side effect . ATI-2042 design reduced plasma half-life low volume distribution , expect result improve safety profile . In contrast amiodarone , ATI-2042 undergo rapid metabolism via plasma tissue esterases , may reduce tissue accumulation toxicity . The current trial determine ATI-2042 retain efficacy profile amiodarone without side effect attributable tissue accumulation see long-term dosing . This study early phase trial specific protocol information proprietary publicly available time . ( Full information available trial participant . )</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Proven paroxysmal atrial fibrillation Pacemaker appropriate AF diagnostics record capability Known allergy Amiodarone previous treatment severe Amiodarone toxicity Cardioversion within one month screen Severe leave ventricular dysfunction CHF NYHA Class III</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>